Market News AIOpen the app

Immuneering showed new research on how atebimetinib could work well with other treatments for pancreatic cancer.

TrialRead the original at globenewswire.com
Good for IMRX

Immuneering reported promising results for atebimetinib combinations, including with chemotherapy and in a pancreatic cancer model. These early lab and animal findings support its trial, but do not prove the treatment works in people.

IMRX · Immuneering Corporation

AI read · Good for IMRX

The AI's read

These results give Immuneering more support for testing atebimetinib with other cancer drugs. The strongest result described came from an animal model, so it cannot show whether patients will benefit. The ongoing study must answer that.

Get alerts for IMRX

Follow Immuneering Corporation (IMRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMRX
Free on the App Store and Google Play, or on the web.